Envestnet Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$221M Sell
1,749,512
-109,500
-6% -$14.4M 0.05% 328
2026
Q1
$259M Buy
1,859,012
+73,345
+4% +$10.3M 0.07% 257
2025
Q4
$219M Sell
1,785,667
-42,729
-2% -$5.19M 0.07% 277
2025
Q3
$203M Sell
1,828,396
-19,579
-1% -$2.23M 0.06% 312
2025
Q2
$205M Buy
1,847,975
+38,568
+2% +$4.1M 0.06% 301
2025
Q1
$203M Sell
1,809,407
-336,251
-16% -$34.7M 0.07% 285
2024
Q4
$198M Sell
2,145,658
-382,884
-15% -$34.5M 0.06% 283
2024
Q3
$212M Buy
2,528,542
+76,259
+3% +$5.82M 0.07% 262
2024
Q2
$168M Sell
2,452,283
-54,929
-2% -$3.67M 0.06% 304
2024
Q1
$184M Buy
2,507,212
+83,479
+3% +$6.42M 0.07% 272
2023
Q4
$196M Sell
2,423,733
-169,506
-7% -$13.2M 0.08% 236
2023
Q3
$194M Buy
2,593,239
+492,471
+23% +$37.9M 0.09% 213
2023
Q2
$162M Sell
2,100,768
-4,542,171
-68% -$362M 0.07% 239
2023
Q1
$190M Buy
6,642,939
+3,915,348
+144% +$324M 0.09% 197
2022
Q4
$234M Buy
2,727,591
+129,435
+5% +$10.3M 0.12% 157
2022
Q3
$160M Buy
2,598,156
+186,332
+8% +$11.7M 0.09% 198
2022
Q2
$149M Buy
2,411,824
+222,391
+10% +$13.8M 0.08% 214
2022
Q1
$130M Buy
2,189,433
+160,481
+8% +$10.3M 0.07% 254
2021
Q4
$147M Buy
2,028,952
+73,714
+4% +$5.08M 0.07% 235
2021
Q3
$137M Sell
1,955,238
-27,069
-1% -$1.9M 0.08% 222
2021
Q2
$137M Buy
1,982,307
+252,245
+15% +$16.8M 0.08% 221
2021
Q1
$112M Buy
1,730,062
+380,145
+28% +$24.5M 0.07% 223
2020
Q4
$78.6M Buy
1,349,917
+47,061
+4% +$2.84M 0.06% 247
2020
Q3
$82.3M Buy
1,302,856
+258,483
+25% +$17.9M 0.07% 205
2020
Q2
$80.4M Sell
1,044,373
-254,686
-20% -$19.5M 0.08% 204
2020
Q1
$97.1M Buy
1,299,059
+12,369
+1% +$855K 0.12% 145
2019
Q4
$83.6M Buy
1,286,690
+46,899
+4% +$3.05M 0.09% 174
2019
Q3
$78.6M Buy
1,239,791
+468,935
+61% +$30.7M 0.09% 176
2019
Q2
$52.1M Sell
770,856
-31,327
-4% -$2.06M 0.07% 223
2019
Q1
$52.1M Buy
802,183
+80,890
+11% +$5.38M 0.07% 202
2018
Q4
$45.1M Buy
721,293
+510,704
+243% +$35.7M 0.07% 198
2018
Q3
$16.3M Sell
210,589
-375,228
-64% -$28.3M 0.03% 216
2018
Q2
$41.5M Buy
585,817
+500,802
+589% +$35.4M 0.09% 108
2018
Q1
$6.35M Sell
85,015
-533,087
-86% -$42.4M 0.02% 336
2017
Q4
$44.3M Sell
618,102
-3,308
-0.5% -$251K 0.1% 109
2017
Q3
$50.4M Buy
621,410
+10,759
+2% +$823K 0.12% 96
2017
Q2
$43.2M Buy
610,651
+82,979
+16% +$5.52M 0.12% 107
2017
Q1
$35.8M Buy
527,672
+151,387
+40% +$10.6M 0.11% 119
2016
Q4
$26.9M Sell
376,285
-25,204
-6% -$1.87M 0.1% 149
2016
Q3
$31.8M Sell
401,489
-58,583
-13% -$4.76M 0.12% 131
2016
Q2
$38.4M Sell
460,072
-17,118
-4% -$1.52M 0.15% 114
2016
Q1
$43.8M Sell
477,190
-89,575
-16% -$8.08M 0.19% 89
2015
Q4
$57.4M Buy
566,765
+12,421
+2% +$1.29M 0.26% 62
2015
Q3
$54.4M Buy
554,344
+83,789
+18% +$9.31M 0.27% 61
2015
Q2
$55.1M Buy
470,555
+1,488
+0.3% +$163K 0.26% 69
2015
Q1
$46M Buy
469,067
+422,763
+913% +$42.9M 0.24% 89
2014
Q4
$4.37M Sell
46,304
-8,015
-15% -$829K 0.04% 239
2014
Q3
$5.78M Buy
54,319
+18,568
+52% +$1.82M 0.06% 228
2014
Q2
$2.96M Buy
35,751
+9,668
+37% +$753K 0.03% 299
2014
Q1
$1.85M Sell
26,083
-11,860
-31% -$930K 0.02% 332
2013
Q4
$2.85M Sell
37,943
-1,512
-4% -$105K 0.03% 262
2013
Q3
$2.48M Sell
39,455
-2,712
-6% -$162K 0.03% 265
2013
Q2
$2.16M Buy
+42,167
New +$2.2M 0.03% 267

Other funds holding GILD

Envestnet Asset Management's GILD Position: Q2 2026 in Review

Envestnet Asset Management reduced its Gilead Sciences (GILD) stake by 5.9% in Q2 2026, selling an estimated $14.4M and leaving 1,749,512 shares worth $221M. The position accounts for 0.05% of the portfolio, ranked #328.

Envestnet Asset Management first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $259M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Envestnet Asset Management held 1,749,512 shares of Gilead Sciences worth $221M as of Q2 2026.
  • Envestnet Asset Management sold 109,500 Gilead Sciences shares in Q2 2026, an estimated $14.4M.
  • Gilead Sciences made up 0.05% of Envestnet Asset Management's portfolio in Q2 2026, its #328 holding.
  • Envestnet Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Envestnet Asset Management's Gilead Sciences position peaked at $259M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.